Name | Number of supported studies | Average coverage | |
---|---|---|---|
interneuron | 6 studies | 23% ± 7% | |
oligodendrocyte precursor cell | 5 studies | 25% ± 6% | |
GABAergic neuron | 5 studies | 30% ± 10% | |
pancreatic A cell | 4 studies | 56% ± 22% | |
endothelial cell | 4 studies | 29% ± 15% | |
neuron | 4 studies | 36% ± 17% | |
type B pancreatic cell | 3 studies | 64% ± 9% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 99% | 3586.89 | 2605 / 2642 | 97% | 56.28 | 682 / 705 |
prostate | 89% | 2808.51 | 218 / 245 | 93% | 43.93 | 467 / 502 |
intestine | 63% | 351.63 | 604 / 966 | 51% | 21.13 | 267 / 527 |
uterus | 69% | 541.49 | 118 / 170 | 42% | 13.28 | 193 / 459 |
ovary | 97% | 4377.71 | 174 / 180 | 13% | 2.14 | 55 / 430 |
adrenal gland | 28% | 299.36 | 72 / 258 | 67% | 108.58 | 153 / 230 |
esophagus | 36% | 383.73 | 514 / 1445 | 34% | 9.30 | 63 / 183 |
pancreas | 29% | 134.66 | 94 / 328 | 41% | 9.96 | 73 / 178 |
stomach | 8% | 36.89 | 29 / 359 | 45% | 23.27 | 128 / 286 |
skin | 1% | 7.04 | 18 / 1809 | 44% | 8.87 | 209 / 472 |
bladder | 5% | 16.86 | 1 / 21 | 32% | 12.48 | 161 / 504 |
tonsil | 0% | 0 | 0 / 0 | 33% | 8.23 | 15 / 45 |
lung | 0% | 0 | 0 / 578 | 29% | 8.97 | 340 / 1155 |
eye | 0% | 0 | 0 / 0 | 25% | 3.71 | 20 / 80 |
lymph node | 0% | 0 | 0 / 0 | 24% | 3.17 | 7 / 29 |
breast | 4% | 17.05 | 19 / 459 | 17% | 7.21 | 192 / 1118 |
liver | 1% | 11.45 | 3 / 226 | 19% | 5.37 | 77 / 406 |
kidney | 9% | 46.47 | 8 / 89 | 3% | 0.62 | 25 / 901 |
thymus | 1% | 2.72 | 4 / 653 | 5% | 0.70 | 30 / 605 |
adipose | 3% | 13.41 | 38 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 0% | 2.53 | 4 / 1335 | 0% | 0 | 0 / 0 |
heart | 0% | 1.21 | 2 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0.49 | 1 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
muscle | 0% | 0 | 0 / 803 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spleen | 0% | 0 | 0 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0007186 | Biological process | G protein-coupled receptor signaling pathway |
GO_0008277 | Biological process | regulation of G protein-coupled receptor signaling pathway |
GO_0030308 | Biological process | negative regulation of cell growth |
GO_0005834 | Cellular component | heterotrimeric G-protein complex |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005886 | Cellular component | plasma membrane |
GO_0031681 | Molecular function | G-protein beta-subunit binding |
GO_0005515 | Molecular function | protein binding |
Gene name | GNG4 |
Protein name | Guanine nucleotide-binding protein subunit gamma Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-4 |
Synonyms | hCG_23460 GNGT4 |
Description | FUNCTION: Guanine nucleotide-binding proteins (G proteins) are involved as a modulator or transducer in various transmembrane signaling systems. The beta and gamma chains are required for the GTPase activity, for replacement of GDP by GTP, and for G protein-effector interaction. . FUNCTION: Guanine nucleotide-binding proteins (G proteins) are involved as a modulator or transducer in various transmembrane signaling systems. The beta and gamma chains are required for the GTPase activity, for replacement of GDP by GTP, and for G protein-effector interaction. . |
Accessions | ENST00000391854.7 P50150 ENST00000366597.5 B1APZ0 ENST00000484517.2 ENST00000450593.5 ENST00000366598.8 |